We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Found for Depression

By Biotechdaily staff writers
Posted on 23 Oct 2005
Based on data from large families in Utah that contain multiple cases of major depressive disorder, scientists have discovered a gene for major depression, the apoptosis protease activating factor 1 (Apaf-1) gene. More...
The finding was reported in the October 18, 2005, online edition of Molecular Psychiatry.

The Apaf-1 gene makes the Apaf-1 protein, an activator of a cascade of events leading to the destruction of a cell. Certain forms of the gene, found to be over-represented in families with major depression, cause a gain of function, leading to increased cell death, or apoptosis. This cell death increase is involved in the cause of major depressive disorder, a hypothesis proposed by scientists at Myriad Genetics, Inc. (Salt Lake City, UT, USA), and supported by their new discovery.

Gain of function variants that cause disease are of special interest to drug developers because it is often easier to block the action of a rogue protein than to restore a lost function. Therefore, drug development scientists at Myriad believe the molecules that inhibit Apaf-1 and its resulting brain cell self-destruction may provide the source of a new class of drugs to treat major depressive disorder.

"We are very excited by the potential of the Apaf-1 gene discovery to lead to new therapeutics for the treatment of depression,” said Peter Meldrum, president and CEO of Myriad Genetics. "There is a real need for novel, more-effective therapies to treat this debilitating disease.”





Related Links:
Myriad Genetics

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.